13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q4 2016. See the latest, Q2 2026 →
Reported value
$274.9M
First quarter on file
Positions
102
First quarter on file
Top 10
48.9%
of the value
Est. gain
—
Nothing to compare
Est. return
—
Nothing to compare
Positions as of Dec 31, 2016, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
Each tile is a position, sized by its share. Striped tiles are options.
Holdings
As of Dec 31, 2016. This is the first quarter on file, so nothing is compared yet.
| Holding | Value | |||||
|---|---|---|---|---|---|---|
| Athenahealth IncCOM | 8.9% | $24.5M | ||||
| Illumina IncCOM | 7.3% | $20.0M | ||||
| Stratasys LtdSHS | 7.0% | $19.1M | ||||
| AmazonCOM | 4.8% | $13.3M | ||||
| NvidiaCOM | 4.0% | $11.1M | ||||
| BaiduSPON ADR REP A | 4.0% | $10.9M | ||||
| NetflixCOM | 3.5% | $9.6M | ||||
| AlphabetCAP STK CL C | 3.4% | $9.4M | ||||
| Proto Labs IncCOM | 3.3% | $9.1M | ||||
| MetaCL A | 2.8% | $7.6M | ||||
| Twitter IncCOM | 2.6% | $7.2M | ||||
| Hortonworks IncCOM | 2.6% | $7.1M | ||||
| SalesforceCOM | 2.0% | $5.5M | ||||
| Splunk IncCOM | 1.9% | $5.3M | ||||
| Invitae CorpCOM | 1.9% | $5.3M | ||||
| Foundation Medicine IncCOM | 1.9% | $5.3M | ||||
| 2u IncCOM | 1.9% | $5.1M | ||||
| Seres Therapeutics IncCOM | 1.8% | $4.9M | ||||
| Lendingclub CorpCOM | 1.7% | $4.8M | ||||
| Bluebird Bio IncCOM | 1.7% | $4.7M | ||||
| Alnylam Pharmaceuticals IncCOM | 1.7% | $4.6M | ||||
| Kite Pharma IncCOM | 1.6% | $4.4M | ||||
| TeradyneCOM | 1.6% | $4.3M | ||||
| 3-D Sys Corp DelCOM NEW | 1.5% | $4.1M | ||||
| Exone CoCOM | 1.5% | $4.0M | ||||
| Total · 102 positions | 100% | $274.9M |
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |